Figures. S1 to S37 23 Tables S1 to S2 24 References for SI reference citations performance liquid chromatography (purity > 95%), were manufactured by Shanghai Sangon 4
Biological Engineering Technology & Services Co. Ltd, and then suspended in TE buffer 5 (Shanghai Sangon) at a final concentration of 100 μM, miR-21, antisense miR-21, miR-200b, 6 antisense miR-200b, and two mismatched oligonucleotides that were purchased from Shanghai 7 GenePharma Co. Ltd (Shanghai, P.R. China). All the reagents used in this study were purchased 8 from Sigma-Aldrich (St. Louis, MO, USA). The deionized (DI) water used throughout the study 9 was obtained with a Milli-Q device (18.2 MΩ; Millipore, Molsheim, France). All glassware 10 was cleaned with freshly prepared aqua regia and rinsed thoroughly with DI H2O before use. 11 The HeLa, MCF-7, and PCS cell lines were obtained from the China Center for Type Culture 12
Collection (Wuhan, P.R. China). 13 Transmission electron microscopy (TEM) images were obtained with a JEOL JEM-2100 14 microscope at an acceleration voltage of 200 kV. The particle size distributions were measured 15 with a Zetasizer Nano ZS system (Malvern) with a 633 nm laser. The ultraviolet-visible (UV- 16 Vis) spectra were obtained with a UNICO 2100 PC UV-Vis spectrophotometer and processed 17 with OriginLab software. UCL spectra were obtained with a Hitachi F-7000 fluorescent 18 spectrometer with an external 980 nm laser as the excitation source. Confocal images of cells 19 were acquired with a modified Olympus FV1000 laser scanning upconversion luminescence 20 microscope equipped with a continuous-wave laser at 980 nm (Connet Fiber Optics, China). A 21 60 × oil-immersion objective lens was used. The laser provided excitation at 980 nm, and the 22 emitted luminescence was collected at 736 ± 50 nm and 588 ± 50 nm. In vivo images of tumors 23 were obtained with the Maestro™ In-Vivo Fluorescent Imaging System (CRi Inc.) using a 980- 24 nm-optical-fiber-coupled laser as the excitation source. 25 Method 26 Synthesis of gold nanorods. Gold nanorods were synthesized using a seed-mediated growth 27 method. The seed solution was prepared as follows: 5 mL of 0.5 mM HAuCl4 and 5 mL of 0.2 28 M CTAB solution were mixed together in a 20 mL scintillation vial. Then 0.6 mL of fresh 0.01 29 M NaBH4 was added to the mixture with vigorous stirring (1200 rpm). Stirring was stopped 30 after 2 min, and the solution color changed from yellow to brownish yellow. The solution was 31 incubated at room temperature for 30 min before use. 32 To prepare the growth solution, 0.617 g of sodium oleate and 3.5 g of CTAB were dissolved in 33 125 mL of warm water. When the solution had cooled to 30 °C, 125 mL of 1 mM HAuCl4 34 solution and 9 mL of 4 mM AgNO3 solution were added. The solution was stirred at 700 rpm 35 for 90 min, and 0.75 mL of HCl (37 wt% in water, 12.1 M) was added to adjust the pH. After 36 another 15 min of stirring (400 rpm), 0.625 mL of 0.064 M ascorbic acid was introduced with 37 vigorous stirring for 30 s. Finally, 0.2 mL of the seed solution was added to the growth solution. 38 The resultant mixture was stirred for 30 s and left undisturbed at 30 °C for 12 h to allow nanorod 39 growth. 40 Preparation of NaGdF4: Yb and Er upconverting nanoparticles (UCNPs). The UCNPs (20 41 ± 3 nm) were synthesized according to the previously reported method, with slight 42 modifications. (1) GdCl3 • 6H2O (0.80 mmol), YbCl3 • 6H2O (0.18 mmol), and ErCl3 • 6H2O 1 (0.02 mmol) were dissolved in a mixture of oleic acid (OA) (14 mL) and octadecene (ODE) 2 (16 mL) in a flask. The solution was heated to 150 °C under nitrogen protection to form a 3 homogeneous solution. Then, methanol solution (10 mL) containing NaOH (0.100 g, 2.5 mmol) 4 and NH4F (0.148 g, 4 mmol) were added slowly. After it had cooled to room temperature, the 5 reaction mixture was stirred at 100 °C under vacuum for 10 min to remove the methanol, and 6 then heated to 320 °C under nitrogen protection and maintained for 1 h. The reaction was 7 terminated by cooling the reaction mixture to room temperature. The resultant nanoparticles, 8
NaGdF4, were precipitated with ethanol, collected by centrifugation, washed several times with 9 ethanol, and then redispersed in tetrahydrofuran (THF) for subsequent experiments. 10 PEG-phosphate ligand (100 mg) was mixed with the OA-coated NaGdF4 nanoparticles (10 mg) 11 in THF (10 mL). The reaction mixture was maintained at room temperature overnight with 12 stirring. The PEG-coated particles were washed three times with cyclohexane, and then dried 13 under vacuum at room temperature. The PEG-coated NaGdF4 particles obtained in this way 14 dissolved readily in aqueous media, independently of the particle size. 15 DNA functionalization of AuNRs and UCNPs. The prepared AuNRs were concentrated 10- 16 fold in 0.005 M CTAB, and then modified with DNA2 (10 μM, dissolved in TE buffer) in a 17 DNA:AuNR molar ratio of 10:1. The mixture was allowed to stand at room temperature for 12 18 h. The modified AuNRs were placed in a centrifuge and spun at 6000 rpm for 5 min (three 19 times) to remove any excess DNA, and then resuspended in 0.001 M CTAB. DNA5 was then 20
added to the AuNRs sample in a 100:1 molar ratio, and the solution was incubated for 12 h with 21 shaking at room temperature. The conjugates were purified by centrifugation at 6000 rpm for 5 22 min to remove the nonconjugated DNA, and resuspended in phosphate buffer (10 mM, pH 7.4) 23 containing 10% CTAB. 24 The water-soluble UCNPs (10 mM) were diluted to 10 nM in phosphate buffer (10 mM, pH 25 7.4). One half of the UCNPs were functionalized with DNA1 in a molar ratio of 5:1. The mixture 26 was incubated for 12 h, and ultrafiltered (30 kDa molecular-weight cut-off) to remove the 27 nonconjugated DNA. TAMRA modified-DNA3 was then added to the mixture to hybridize 28 with DNA1. After incubation for 12 h, the final UCNP bioconjugate was purified using 29 ultracentrifugation at 8000 g for 10 min, suspended in PB buffer and stored at 4 °C. The other 30 half of the UCNPs were functionalized with DNA4 and DNA6 under the same conditions. 31
Assembly of AuNRs and UCNPs into core-satellite superstructures. The purified DNA2, 32 DNA5-modified AuNR core, the DNA1, and DNA3-modified UCNPs or DNA4, and DNA6-33 modified UCNPs satellites in a molar ratio of 1:20:100 were mixed in hybridization buffer (10 34 mM PBS [pH 7.4], 5 mM MgCl2, 0.01% Tween 20). The mixture was incubated in a 60 °C 35 water bath for 60 min and then cooled to 37 °C for 12 h. When the assembly of the 36 AuNR@UCNP core-satellite was complete, thiolated PEG (5 kDa) was added to the core-37 satellite solution in a molar (PEG:AuNR core) ratio of 3000:1 and kept at 60 °C for 30 min in 38 a water bath. The modified core-satellite assembly was then placed in a centrifuge at 6000 rpm 39 for 5 min, and then suspended in PBS. 40 miR-200b and miR-21 detection in vitro.
To determine the detection sensitivity of the 41 assembly in vitro, the assembly in 10 mM PBS buffer was spiked simultaneously with different 42 concentrations of miR-200b and miR-21. After incubation for 1 h at 37 °C, the fluorescent 43 signals were obtained under 980 nm excitation and the power is 500 mW. 44
To measure the feasibility and selectivity of the AuNR@UCNP core-satellite assembly, the 1 target miRNAs (miR-200b and miR-21), miR-203 b , let-7d, bovine serum albumin (BSA), 2 glutathione (GSH), and mismatched sequences were added to the detection solution for 1 h (24 3 h for the BSA and GSH samples) at 37 °C, and the fluorescence was measured after the reaction. 4 Fluorescence signals were acquired under 980 nm excitation and the power is 500 mW. 5
Cell lines and incubation conditions. HeLa (human epithelial carcinoma) cells, MCF-7 6 (human breast cancer) cells, and PCS-460-010 (normal human epithelial) cells were purchased 7 from the American Type Culture Collection (Manassas, VA). The cells were cultured in 8
Dulbecco's modified Eagle's medium containing 10% fetal bovine serum and 1% 9 penicillin/streptomycin at 37 °C under a 5% CO2 atmosphere. The cell numbers were counted 10 with a Petroff-Hausser cell counter (USA). Serum-free medium (Opti-MEM; Life 11
Technologies) was used for the transfection process. 12
Cell viability assessment. To evaluate the cytotoxicity of the AuNR@UCNP assembly, HeLa 13 cells were seeded in RPMI-1640 medium with 10% fetal bovine serum in a 96-well plate, with 14 five wells for each concentration of the assembly. The cells were incubated at 37 °C for 24 h in 15 culture medium. Different concentrations of the assembly, modified with cell penetrating 16 peptides (TAT), were then added to the culture medium and incubated for 24 h. The culture 17 medium was replaced with 100 μL of fresh Opti-MEM (Life Technologies) and the cells were 18 treated with 10 μL of Cell Counting Kit-8 (CCK-8, Beyotime) for 4 h. The absorbance (A) of 19 each well was measured on a microplate reader at 450 nm, and the relative cell viability (%) 20 was calculated as (Atest/Acontrol) × 100. The viability of cells treated with the assembly for 21 different incubation periods was also measured with the CCK-8 assay. 22 HeLa cells were seeded in a 35 mm Petri dish at a density of 10 4 cells per well for 24 h. 23 The cells were incubated with 200 µL of various assemblies for 24 h at 37 °C. The excess 24 assemblies were removed and the cells were washed with PBS, and then fixed with 4% 25 paraformaldehyde in PBS for 15 min. The cells were co-stained with the LIVE/DEAD Cell 26 Imaging Kit (Thermo Fisher Scientific Inc.) for 30 min, washed with PBS, and examined with 27 Leica laser scanning confocal microscopy with 488 nm and 552 nm laser irradiation, and the 28 power is 200 mW. 29
Quantitation of number of TAT peptides per AuNR@UCNP. The number of TAT peptides 30 that are conjugated to the AuNR@UCNP can be measured using the following procedure.(2, 3) 31 (1) Label TAT peptide with FAM fluorescent dyes using a standard labeling kit. 32 (2) Then, determine a linear calibration curve that relates the concentration of a fluorescently 33 labeled TAT peptide and fluorescence intensity. 34 (3) TAT peptide solution (5 mM) was added, with a peptide-to-AuNR@UCNP ratio of 1000:1. 35 The solution was incubated for 24 h followed by removal of the un-coupled peptide though 36 centrifugation. The fluorescence signals from the supernatant at the 490 nm excitation/518 nm 37 emission wavelengths of the FAM were used to tag TAT peptide. 38 (4) Use the calibration curves to determine the concentration of TAT peptide in the supernatant. 39 Subtract these values from the initial concentrations to obtain the amount of TAT peptide that 40 is attached to AuNR@UCNP. 41 (5) To measure the initial concentrations, prepare TAT peptide solutions at exactly the same 42 concentrations as in the reaction mixture with AuNR@UCNP. 43 Calculating intracellular miR-21 and miR-200b in Hela cells. The synthetic miR-21 and 1 miR-200b were measured with the TaqMan ® MicroRNA Assay (Fig. S15, Fig. S17 ), and 2 standard curves of the cycle threshold values (Ct) versus the concentrations of miR-21 and miR-3
200b were constructed (Fig. S16, Fig. S18 ). The RT-qPCR amplification plots of the miR-21 4
and miR-200b extracted from the regulated cells were constructed, and the Ct values for miR-5 21 and miR-200b were then read from Fig. S19 and Fig. S20 , respectively. The amounts of 6 miR-21 and miR-200b in the six samples were calculated from the standard curves in Fig. S16  7 and Fig. S18 , respectively. Reagent (Life Technologies), according to manufacturer's instructions. Every cell medium was 13 replaced with 10 mL of Opti-MEM containing RNAiMAX (300 μL) and the cells were 14 transfected with miR-21 (1, 10 pM) and miR-200b (2, 10 pM), or antisense miR-21 (1, 10 pM) 15 and miR-200b (2, 10 pM) for 24 h. After transfection, the intracellular miR-21 and miR-200b 16 concentrations were quantified using a commercially available miR-specific qRT-PCR kit, and 17 then for the following experiments. 18 Quantification of miR-200b and miR-21 in transfected HeLa cells. Confocal imaging of cellular miR-200b and miR-21. The transfected HeLa cells expressing 23 different levels of miR-21 and miR-200b were cultured on glass-bottomed Petri dishes (for 24 confocal microscopy; Nest Biotechnology Co., Ltd) for 12 h, at an initial density of 2 × 10 4 25 cells/dish. Then, the cells were incubated with the AuNR@UCNP probe for 8 h, After culture, 26 the cells were washed three times with cold PBS to remove any extracellular assembly. 27 Confocal images of the treated cells were obtained with confocal fluorescence microscopy. The 28 fluorescence of the assembly was excited at 980 nm and the power is 500 mW, the fluorescent 29 images were collected at 588 ± 50 nm and 736 ± 50 nm. The experiments were repeated three 30 times with similar results. 31
Animal tumor models. All animal experiments conformed to the guidelines of the Chinese 32 Animal Use and Care Committee. Five-week-old female nude mice were subcutaneously 33 inoculated above the right flanks with 5 × 10 6 HeLa cells suspended in 50 µL of cold PBS. The 34 in vivo studies were performed after 3 weeks. The AuNR@UCNP assembly (200 μL, in terms of the amount of AuNR, 2 mg/mL) was 3 intravenously injected into the nude mice. After 0 h, 12 h, and 24 h, fluorescent images of the 4 flanks of the live mice were taken under a 980 nm laser excitation and the power is 500 mW. 5
Western Blot analysis. In the Western Blot analysis, tumor tissues were lysed with RIPA Lysis 6
Buffer (Beyotime). The protein lysates were separated with SDS-PAGE and then transferred to 7 polyvinylidene difluoride (PVDF) membranes (Life Technologies). The membranes were 8 incubated with primary antibody against PDCD4 or CCND1 (diluted 1:1000), and then with a 9
horseradish-peroxidase-conjugated secondary antibody (1:1000 dilution). Tubulin (1:1000 10 dilution) was used as the loading control. 11
Histopathological examination. After the delivery of different concentrations of miRNA 12 inhibitors, the AuNR@UCNP assembly (200 μL, 2 mg/mL, in terms of the amount of AuNR) 13 was injected through the tail veins of the mice. After 24 h, the tumors were harvested and fixed 14 in 10% formalin solution for 12 h. The prepared tumor samples were refrigerated, sliced into 5 15 µm sections, and mounted on glass slides. Images of the treated tumor sections were obtained 16 with confocal fluorescence microscopy. Fluorescence images were acquired with for 980 nm 17 excitation and 500 mW power. 
